



Immunic
THERAPEUTICS

Immunic Therapeutics

Developing Selective Oral Therapies in Immunology

NASDAQ: IMUX | October 2024

Cautionary Note Regarding Forward-Looking Statements

→ This presentation contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These include statements regarding management’s intentions, plans, beliefs, expectations or forecasts for the future, and, therefore, you are cautioned not to place undue reliance on them. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Immunic undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by law. We use words such as “anticipates,” “believes,” “plans,” “expects,” “projects,” “future,” “intends,” “may,” “will,” “should,” “could,” “estimates,” “predicts,” “potential,” “continue,” “guidance,” and similar expressions to identify these forward-looking statements that are intended to be covered by the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995.

→ Such forward-looking statements are based on our expectations and involve risks and uncertainties; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including, but not limited to, risks relating to strategy, future operations, future financial position, future revenue, projected expenses, prospects, plans and objectives of management. Risks and uncertainties that may cause actual results to differ materially from those expressed or implied in any forward-looking statement include, but are not limited to: Immunic’s development programs and the targeted diseases; the potential for Immunic’s development programs to safely and effectively target and treat the diseases mentioned herein; preclinical and clinical data for Immunic’s development programs; the impact of future preclinical and clinical data on Immunic’s product candidates; the timing of the availability of data from Immunic’s clinical trials; the availability or efficacy of Immunic’s potential treatment options that may be supported by trial data discussed herein; the timing of current and future clinical trials and anticipated clinical milestones; Immunic’s ability to protect its intellectual property position; Immunic’s plans to research, develop and commercialize its current and future product candidates; the timing of any planned investigational new drug application or new drug application; the development and commercial potential of any product candidates of the company; expectations regarding potential market size; developments and projections relating to Immunic’s competitors and industry; the clinical utility, potential benefits and market acceptance of Immunic’s product candidates; Immunic’s commercialization, marketing and manufacturing capabilities and strategy; Immunic’s ability to successfully collaborate with existing collaborators or enter into new collaboration agreements, and to fulfill its obligations under any such collaboration agreements; Immunic’s ability to identify additional products or product candidates with significant commercial potential; the impact of government laws and regulations; the COVID-19 pandemic; impacts of the conflicts in Ukraine – Russia and the Middle East; Immunic’s listing on The Nasdaq Global Select Market; expectations regarding the capitalization, resources and ownership structure of the company; the executive and board structure of the company; Immunic’s estimates regarding future revenue, expenses, capital requirements and need for additional financing, including the ability to satisfy the minimum average price and trading volume conditions required to receive funding in tranche 2 and 3 of the January 2024 private placement; the nature, strategy and focus of the company and further updates with respect thereto; and the other risks set forth in the company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission.

→ Forward-looking statements included in this presentation are based on information available to Immunic as of the date of this presentation. Immunic does not undertake any obligation to update such forward-looking statements except as required by applicable law.

CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY (NASDAQ: IMUX)

Dedicated to improving the lives of patients with
chronic inflammatory and autoimmune diseases



Innovative pipeline:
First-in-class oral drugs with unique
modes of actions for multiple
sclerosis and gastrointestinal diseases



Experienced leadership team:
Successfully developed and
commercialized multiple medicines



Near-term catalysts:
Series of milestones targeting
significant market opportunities



Large commercial opportunity:
Blockbuster potential for Phase 3
program in multiple sclerosis



Financials:
Cash balance of USD 79.7 million
expected to support operations into
Q3/2025

Leadership Team

Company is Led by an Experienced Management Team



Daniel Vitt,
PhD
Chief Executive
Officer



Jason Tardio,
MBA
President & Chief
Operating Officer




Andreas Muehler,
MD, MBA
Chief Medical
Officer



Hella Kohlhof, PhD
Chief Scientific
Officer



Glenn Whaley, CPA
Chief Financial
Officer



Patrick Walsh
Chief Business
Officer



Inderpal Singh
General Counsel



Werner Gladdines
Chief Development
Officer



Duane Nash,
MD, JD, MBA
Executive
Chairman

Advanced Clinical Pipeline

Well Differentiated Programs in Various Phases of Clinical Development

| Program | Preclinical | Phase 1 | Phase 2 | Phase 3 | Key Program Updates |
|---------------------------------------|---|---------|---------|---------|---|
| Vidofludimus Calcium (IMU-838) | | | | | ✓ Phase 2 EMPHASIS trial in relapsing-remitting MS successfully completed |
| | Relapsing Multiple Sclerosis (RMS) – ENSURE-1 and ENSURE-2 Trials | | | | ✓ Interim futility analysis of ENSURE program completed, IDMC recommendation to continue trials as planned |
| | | | | | ✓ Interim biomarker readout of CALLIPER trial completed with strong NfL reduction effects |
| | Progressive Multiple Sclerosis (PMS) – CALLIPER Trial | | | | ✓ Phase 2 CALDOSE-1 trial in UC completed, effective in 50 weeks maintenance phase |
| | | | | | <ul style="list-style-type: none"> Top-line data from CALLIPER trial expected in April 2025 Completion of first ENSURE trial expected in Q2/2026, second in H2/2026 |
| IMU-856 | | | | | ✓ Phase 1/1b trial in healthy volunteers and celiac disease patients completed, achieved first proof-of-concept in celiac disease |
| | Celiac Disease and other Gastrointestinal Disorders | | | | <ul style="list-style-type: none"> Phase 2 clinical trial in preparation |
| IMU-381 | | | | | |
| | Gastrointestinal Diseases | | | | |

■ Ongoing ■ Completed ■ In preparation or planned



Vidofludimus Calcium in Multiple Sclerosis (MS)

Targeted to Elevate the Standard
of Care for the Full Spectrum of
Multiple Sclerosis Patients

Vidofludimus Calcium Has the Potential to Transform the Oral Multiple Sclerosis DMT Market

Designed to Combine the Best of Two Worlds: Neuroprotection and Relapse Prevention

First-in-class, dual mode of action approach designed to address the **full spectrum of disease**:

- Nurr1 activation provides **direct neuroprotective effects**
- DHODH inhibition is associated with **anti-inflammatory effects**

Oral DMT category: Achieves **best-in-class benefit / risk profile** by combining **strong efficacy** with **safety, tolerability**, and **once-daily** convenience

No first-dose or on-treatment monitoring makes it an **easy start or switch to therapy**

No anticipated black box warnings or serious infection risk (e.g., PML, malignancies, etc.)



→ **If approved, peak sales potential for vidofludimus calcium of \$2-6 billion^[1]**

DMT: disease-modifying therapy; Nurr1: nuclear receptor related 1; DHODH: dihydroorotate dehydrogenase; PML: progressive multifocal leukoencephalopathy [1] Based on Immunic internal market research

Multiple Sclerosis is a Lifelong Neurodegenerative Disease




Lifelong Disease Requiring Decades of Therapy

- ~2.9 million people affected worldwide^[1]
- ~1 million people affected in US^[1]
- Often diagnosed in younger adults (3:1 women:men)



Therapeutic Goal: Increase Independence

- Key unmet need: prevention or slowing of long-term disability worsening, prolonging time of independence
- Historical focus has been on prevention of relapses via broad immunosuppression




[1] National MS Society (2024): How Many People Live With Multiple Sclerosis? <https://www.nationalmssociety.org/understanding-ms/what-is-ms/who-gets-ms/how-many-people#:~:text=An%20Overview%20of%20How%20Many,than%20twice%20the%20previous%20estimate>
Illustration adapted from: VOX, <https://futurism.com/reversal-of-multiple-sclerosis-via-risky-stem-cell-treatment-confirmed>, and Multiple Sclerosis Trust, <https://www.mstrust.org.uk/>

The Unmet Medical Needs in Multiple Sclerosis



Despite Being on Efficient Relapse-Targeting Therapies, Majority of Patients Still Experiences Disability Worsening^[1]




Goals for New Multiple Sclerosis Treatments

- Developing a new therapy offering:
 - Neuroprotection and effect on progression independent of relapse activity (PIRA)
 - Excellent safety and tolerability
 - Easy to use, convenient oral administration without complex screening requirements
- Developing a new therapy for newly diagnosed patients and as an excellent switch opportunity

[1] Quantitative survey performed by Immunic, 100 MS patient respondents, US based / DMT: disease modifying therapy; PIRA: progression independent of relapse activity

Underlying “Invisible Disability Accumulation” Contributes to Disability Progression Over Time Requiring a Dual Mode of Action Approach



Graphic adapted from Kretzschmar A., Symposium MSVirtual2020 / 8th Joint ACTRIMS-ECTRIMS Meeting and REVIEW article, Front. Immunol., 29 November 2023, Sec. Multiple Sclerosis and Neuroimmunology, Volume 14 – 2023 [1] Scalfari A. Mult Scler. 2021 Jun;27(7):1002-1004 / MRI: magnetic resonance imaging; Nurr1: nuclear receptor related 1; DHODH: dihydroorotate dehydrogenase; DMT: disease modifying therapy; MS: multiple sclerosis

These observations challenge the dichotomy between relapsing and progressive disease, supporting a one stage disorder model of MS, where all patients exhibit a **progressive course from the disease onset**, which can be overlapped by relapses.^[1]


The ideal DMT agent will have a significant impact on relapses and focal MRI activity to reduce RAW but also halts the putative processes responsible for smoldering MS/PIRA.

There Are Three Distinct MS Indications

The Different Indications Have Different Paths and Drivers of the Disability Progression


Relapsing MS

- Includes relapsing-remitting MS and active secondary progressive MS
- Relapses and MRI lesions dominate clinical course, disability progression already present
- Current drugs mainly address relapses and relapse-associated disability worsening




Non-Relapsing SPMS

- Relapses have stopped, but disability progression continues
- No therapies approved, to date



Primary Progressive MS

- Disability worsening without relapses from the start without predominance of relapses
- Only one drug approved, so far



Adapted from Kretschmar A., MSVirtual2020; *Lublin FD, et al. Brain. 2022 Sep 14;145(9):3147-3161

MS: multiple sclerosis; MRI: magnetic resonance imaging; RRMS: relapsing-remitting MS; SPMS: secondary progressive MS; aSPMS: active SPMS


A Large and Growing Global Market Where Multiple Blockbusters Coexist

Many brands are generating in excess of \$1 billion in global annual sales in 2023^[1]

| | |
|------------------------|---------------|
| Ocrevus® | \$7.2 billion |
| Kesimpta® | \$2.2 billion |
| Tysabri® | \$1.9 billion |
| Tecfidera® & Vumerity® | \$1.6 billion |
| Avonex® & Plegridy® | \$1.1 billion |
| Mavenclad® | \$956 million |
| Aubagio® | \$955 million |
| Gilenya® | \$925 million |
| Rebif® | \$709 million |
| Briumvi® | \$89 million |


\$20 billion market today growing 4% y/y^[2]

Major market sales of MS therapies(\$ billion)



[1] Company public filings [2] Sales numbers in G7 countries (US, UK, Canada, Japan, Germany, France, Italy) in USD billion; Multiple Sclerosis Landscape and Forecast by Decision Resources Group Part of Clarivate

Oral DMTs Will Continue to Play a Big Role as Important Treatment Options



While the anti-CD20 class of therapies continues to grow, the oral class still captures over 1/3 of the global market

- Data supports that 42% of patients prefer oral medicines^[2]
- Early-line reliance on injectable therapies will continue to wane as the market shifts to using oral therapies earlier
- 15% of patients with PPMS and 25% of patients with non-active SPMS received oral treatments (off label)^[3]

[1] Sales numbers in G7 countries (US, UK, Canada, Japan, Germany, France, Italy) in USD billion; 2024 Multiple Sclerosis Landscape and Forecast by Decision Resources Group Part of Clarivate. [2] Jonker MF, et al. Med Decis Making. 2020 Feb;40(2):198-211 [3] Watson C, et al. Neurol Ther. 2023 Dec;12(6):1961-1979 / DMT: disease-modifying therapy; CD20: B lymphocyte cell-surface molecule; SPMS: secondary progressive MS; PPMS: primary progressive MS

Multiple MS Patient Segments Could Benefit from Vidofludimus Calcium




Newly diagnosed patients



Patients switching therapies due to disability worsening



Patients switching therapies due to tolerability or safety concerns



Older patients where immunosuppression is a concern



Untreated patients



Patients with progressive disease (nrSPMS & PPMS)



nrSPMS: non-relapsing secondary progressive MS; PPMS: primary progressive MS

Vidofludimus Calcium: Derisked Near-Term Opportunity with \$2-6 Billion Peak Potential



Indication



Status



Clinical Evidence



Eligible Population



Next Milestones



Potential Peak Sales

RMS

Phase 3

76% reduction in new Gd+ lesions (Phase 2)

~900k

Futility interim analysis **Q4/2024**
Phase 3 completion **2026**

\$1-2B

nrSPMS

Phase 2

20.1% reduction in serum NfL compared to placebo in nrSPMS patients (Phase 2)

~175k

Phase 2 data **April 2025**

\$1-2B

PPMS

Phase 2

18.8% reduction in serum NfL compared to placebo in PPMS patients (Phase 2)

~120k

Phase 2 data **April 2025**

\$1-2B

Patient numbers sourced via internal Immunic analysis and the 2024 Multiple Sclerosis Landscape and Forecast report by Decision Resources Group Part of Clarivate
RMS: relapsing MS; nrSPMS: non-relapsing secondary progressive MS; PPMS: primary progressive MS; Gd+: gadolinium-enhancing; NfL: neurofilament light chain



Vidofludimus Calcium in Multiple Sclerosis (MS)

First-in-Class, Potent
Nurr1 Activator and
Selective DHODH Inhibitor


Vidofludimus Calcium Addresses Smoldering Neurodegeneration



First-in-Class Nurr1 Activator, Targeting Improvement of Physical and Mental Ability of Multiple Sclerosis Patients

Nurr1 Activator

- Direct and indirect neuroprotective effects
- Involved in protecting relevant neurons from cell death
- Known effects reducing activation of microglia and astrocytes
- Effect independent from focal inflammation




DHODH Inhibitor

- Selectively targets hyperactive immune cells
- Selective anti-inflammatory effects, reducing focal inflammation, magnetic resonance imaging lesions and relapses
- Broad-spectrum antiviral effects prevent reactivation of EBV and could stop cross reactive immune responses



Blocking of
Th17/Th1 cytokines




Nurr1: nuclear receptor related 1; DHODH: dihydroorotate dehydrogenase; EBV: Epstein-Barr virus

Nurr1 Is a Nuclear Receptor Involved in Neuroprotection


Nurr1 is expressed in different cells relevant for neuroprotection

microglia




Nurr1 activation prevents microglia/
astrocyte-driven neurotoxicity in the brain

astrocyte



neuron



Nurr1 activation mediates neuronal survival
Nurr1 activation in motor neurons may halt
neurodegeneration and disability progression



Nurr1 activation by vidofludimus calcium leads to induction of primary target genes in these cells

Vietor et al., Journal of Medicinal Chemistry 2023 66 (9), 6391-6402; Schiro et al., 2022, Frontiers in Neurology, adapted from Willems S, Merk D. J Med Chem. 2022;65(14):9548-9563; illustrations created in BioRender.com; Nurr1: nuclear receptor related 1



Vidofludimus Calcium Activates Nurr1, Postulated to Increase Neuronal Survival



Nurr1 Binding

Nurr1 is a transcription factor binding to DNA^[1]


Vidofludimus calcium binds to and strongly activates Nurr1 activity with nM values



Gene Expression Regulation

Vidofludimus calcium induces a > 2-fold induction of target gene expression of VMAT2 at 30 nM concentration^[2]


Human microglia cells (HMC3)



Improves Neuronal Survival

Vidofludimus calcium improves neuronal survival via Nurr1 activation^[3]

N2A cells



[1] Vieter et al., Journal of Medicinal Chemistry 2023 66 (9), 6391-6402 The related research project was funded by the German Federal Ministry of Education and Research under the grant number 03INT607AA; Structure: Zhao, M. et al. (2022) Proc Natl Acad Sci USA 119;
[2] Sun, Zuoming. City of Hope. 2023, unpublished [3] Unpublished data: Sun lab, City of Hope, Duarte; 2023 / Nurr1: nuclear receptor related 1; DNA: deoxyribonucleic acid; VMAT2: vesicular monoamine transporter 2; DMSO: dimethyl sulfoxide; TNF: tumor necrosis factor

Vidofludimus Calcium: General Effects on MS Disease Processes


2

Improving the survival of neurons in a neurotoxic environment

Nurr1 Activation

1


Reducing the activation of microglia (which are a source of a neurotoxic environment)



3

Targeting metabolically active immune cells involved in MS


DHODH Inhibition



B & T cells


4

Reducing smoldering disease by blocking the constant trigger of immune cells via inhibition of EBV reactivation



Nurr1: nuclear receptor related 1; DHODH: dihydroorotate dehydrogenase; EBV: Epstein-Barr virus

Vidofludimus Calcium: Clinical Trials Overview in Multiple Sclerosis (MS)





Vidofludimus Calcium in Multiple Sclerosis (MS)


Development in Relapsing Multiple Sclerosis (RMS)

Vidofludimus Calcium Could be the First Treatment Option for Relapsing MS Fulfilling the Current Unmet Needs of Patients



Goals for New Relapsing Multiple Sclerosis Treatments

- Developing a new therapy offering:
 - Neuroprotection and effect on progression independent of relapse activity (PIRA)
 - Excellent safety and tolerability
 - Easy to use, convenient oral administration without complex screening requirements
- Developing a new therapy for newly diagnosed patients and as an excellent switch opportunity



EMPhASIS: Completed Phase 2 Trial in Relapsing-Remitting MS

NCT03846219



Coordinating Investigator

Robert J. Fox, M.D.
Cleveland Clinic



Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Trial

- Blinded main treatment period of 24 weeks
- Cohort 1: 30 and 45 mg or placebo QD
- Cohort 2: 10 mg or placebo QD
- Extended treatment period of up to 9.5 years ongoing to observe long-term safety is ongoing



Trial Met Key Efficacy and Safety Endpoints


- Randomized 268 patients in 36 centers across four European countries
- Vidofludimus calcium showed strong activity in relapsing-remitting MS population
 - Primary and key secondary endpoints met with high statistical significance: strong reduction of MRI lesion activity
 - Reduced serum NfL concentrations
 - Signal in preventing confirmed disability worsening
- Vidofludimus calcium's safety profile was similar to placebo
 - No general safety signals observed
 - Low discontinuation rates, considerably lower than placebo

MS: multiple sclerosis; QD: quaque die = once-daily; MRI: magnetic resonance imaging; NfL: neurofilament light chain


EMPhASIS: Strong Reduction of MRI Lesion Activity

Primary Endpoint Hit With High Statistical Significance, Pooled Cohorts 1 & 2

Reduction in Cumulative CUA Lesions up to Week 24




Reduction in Gd+ Lesions up to Week 24



Primary and key secondary endpoints of cumulative number of new CUA lesions up to week 24 met with high statistical significance (primary 45 mg vs. placebo: $p = 0.0002$ / key secondary 30 mg vs. placebo: $p < 0.0001$)

As Cohort 2 only allowed MRI machines of 1.5T, pooled data of Cohorts 1 & 2 only include patients that were evaluated at MRI field strength of 1.5 Tesla. Modified full analysis set C1/C2 (N10 = 47, N30 = 65, N45 = 66, NPBO C1 = 59, NPBO C2 = 12). Data displayed are as adjusted mean values. Estimates are adjusted for baseline volume of T2 lesions and baseline number of Gd+ lesions (0, >=1) using a generalized linear model with a negative binomial distribution and a logarithmic link function. Log transformation of time from first investigational medicinal product (IMP) dose to date of last MRI assessment with non-missing values is used as offset term / RMS: relapsing-remitting multiple sclerosis; MRI: magnetic resonance imaging; CUA: cumulative unique active, Gd+: gadolinium-enhancing

EMPhASIS: Reduction of Serum NfL Concentrations Observed Versus Placebo After 24 Weeks, Pooled Cohorts 1 & 2



Vidofludimus calcium showed a remarkable reduction in NfL levels in all active doses tested compared with placebo


- The relative change of serum NfL versus placebo is proportional to vidofludimus calcium dose.
- Higher doses are expected to show stronger neuroprotective effects.

Displayed are median values of differences between percentage change of serum neurofilament light chain concentration (Hodges-Lehmann estimation), treatment vs. placebo
Data shows 10 mg versus placebo for Cohort 2 and 30/45 mg versus placebo for Cohort 1; NFL: neurofilament light chain

EMPhASIS: Reduced Confirmed Disability Worsening Events

End of 24-Week Blinded Treatment Period

CDW Events at the End of the 24-Week Blinded Treatment Period



Data confirms a signal in preventing 12-week and 24-week confirmed disability worsening events as compared to placebo. Confirmatory data will be obtained in the phase 3 ENSURE clinical program.

CDW: confirmed disability worsening; EDSS: Expanded Disability Status Scale

Only disability worsenings with a trigger point during the 24-week blinded treatment period are considered. The EDSS increases during the blinded treatment phase were subsequently confirmed during open-label extension phase of the trial. Patients at risk in this analysis are 187 for vidofludimus calcium (pooling 10, 30 and 45 mg data) and 81 for placebo. The trigger event is an EDSS progression defined as an increase in the EDSS compared to Baseline of at least 1.5 points if Baseline EDSS = 0, of at least 1.0 points if Baseline EDSS of 1-5, or of at least 0.5 points if Baseline EDSS ≥ 5.5

12-week CDW: The confirmation event is at least 77 days after the trigger event. At the confirmation event and each assessment between trigger and possible confirmation event, EDSS must be at least as high as at the trigger event.


24-week CDW is defined analogously, the only difference being the time interval between trigger event and confirmation visit, which is at least 161 days.

Full analysis set pooled cohorts 1&2 (N10 = 47, N30 = 71, N45 = 69, NPBO C1 = 69, NPBO C2 = 12)

EMPhASIS: Low Rates of Confirmed Disability Worsening Events

Interim Analysis Open-Label Extension Period 12-Week CDW Events

Proportion of patients free of 12-week confirmed disability worsening after 1 and 2 years of open-label extension vidofludimus calcium treatment




Data confirms that only a few patients on continuous treatment with vidofludimus calcium develop 12-week confirmed CDW events over a 2-year time frame.

CDW: confirmed disability worsening; EDSS: Expanded Disability Status Scale; Only disability worsenings compared to start of extended treatment are considered. Patients at risk in this analysis are 223 at 48 weeks and 158 for 96 weeks. This includes all patients randomized to either placebo or any dose of vidofludimus calcium. After 24 week of blinded treatment, all patients continued with open-label treatment with either 30 mg or 45 mg vidofludimus calcium. Survival rates and times estimated by the Kaplan-Meier method. 95% CI for rates based on Greenwood's formula.; The trigger event is an EDSS progression defined as an increase in the EDSS compared to Baseline of at least 1.5 points if Baseline EDSS = 0, of at least 1.0 points if Baseline EDSS of 1-5, or of at least 0.5 points if Baseline EDSS ≥ 5.5
12-week CDW: The confirmation event is at least 77 days after the trigger event. At the confirmation event and each assessment between trigger and possible confirmation event, EDSS must be at least as high as at the trigger event.

EMPhASIS: 12-Week Confirmed Disease Worsening After 2 Years

Interim Analysis Open-Label Extension Period Compared to Select Historical Trials

RRMS patients with 12-week (3-months) confirmed disability worsening after 2 Years (96 Weeks) (% of patients at risk)



The trigger event is any EDSS progression during the open-label extension (OLE) period defined as an increase in the EDSS compared to start of the OLE period (Baseline) of at least 1.5 points if Baseline EDSS = 0, of at least 1.0 points if Baseline EDSS of 1-5, or of at least 0.5 points if Baseline EDSS ≥ 5.5. Patients with RRMS at risk in this EMPhASIS analysis are 158 at 96 weeks. Data cut-off was Oct 16, 2022. This includes all patients randomized to either placebo or any dose of vidofludimus calcium during the 24-week blinded treatment period and then continued with open-label treatment with either 30 mg or 45 mg vidofludimus calcium. Survival rates and times estimated by the Kaplan-Meier method. 95% CI for rates based on Greenwood's formula.; 12-week CDW: The confirmation event is at least 77 days after the trigger event. At the confirmation event and each assessment between trigger and possible confirmation event, EDSS must be at least as high as at the trigger event.; 24-week CDW is defined analogously, the only difference being the time interval between trigger event and confirmation visit, which is at least 161 days.; KM: graphical estimates from published Kaplan-Meier curves; EDSS: Expanded Disability Status Scale; RRMS: relapsing-remitting multiple sclerosis. All trials performed in RRMS. Vidofludimus Calcium: Immunic data; OPTIMUM: Kappos et al. 2021; ASCLEPIOS: Hauser et al. 2020; OPERA: Hauser et al. 2017

Unrivaled Safety and Tolerability Profile Observed for Vidofludimus Calcium in Multiple Clinical Trials

- Safety profile similar to placebo: no general safety signals observed in clinical trials so far
- No increased rates of diarrhea, neutropenia, or alopecia
- No increased rates of infections and infestations or hematology values
- Drug exposure tested in more than 1,800 human subjects and patients, to date
- Low rates of adverse events
- No signals for hepatotoxicity or elevations of liver enzymes and no Hy's law cases observed to date



Vidofludimus Calcium's Safety Profile to Date is Unique

| | PML risk | Increased number of infections | Vaccination limitations | Gastrointestinal toxicities, incl. diarrhea | Cardiovascular risks, incl. blood pressure | Lymphopenia | Neutropenia | Risk of liver injury | Increased risk of cancer | Macular edema |
|----------------------|----------|--------------------------------|-------------------------|---|--|-------------|-------------|----------------------|--------------------------|---------------|
| Vidofludimus Calcium | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● |

● Favorable profile

PML: progressive multifocal leukoencephalopathy

EMPhASIS: Patients Feel Well-Treated With Vidofludimus Calcium



Reflected in **Low Discontinuation Rates** for Vidofludimus Calcium-Treated RRMS Patients, Considerably Lower Than Placebo*

| | Vidofludimus Calcium | Glatiramer Acetate ^[1] | Aubagio® ^[2] | Tecfidera® ^[3] | Gilenya® ^[4] | Zeposia® ^[5] |
|------------------|----------------------|-----------------------------------|-------------------------|---------------------------|-------------------------|-------------------------|
| Administration | Oral | Injectable | Oral | Oral | Oral | Oral |
| Daily Dose | 30 mg QD | 20 mg QD | 14 mg QD | 240 mg TID | 1.25 mg QD | 1 mg QD |
| Treatment Period | 24 weeks | 9 months | 36 weeks | 24 weeks | 6 months | 24 weeks |
| Active Treatment | 2.8% | 5.9% | 19.3% | 15.6% | 5.4% | 2.3% |
| Placebo | 7.2% | 5.8% | 6.6% | 9.2% | 6.5% | 3.4% |

*The table summarizes the data on treatment/study discontinuation rates of the commercial dose in phase 2 trials of RRMS drugs. If the commercial dose was not included in the phase 2 trials, the dose closest to the commercial dose was shown. This high-level comparison is provided for illustrative purposes only, is based on publicly available data and does not purport to be a comprehensive comparison or depiction of the other trials. Larger data sets than presented in this presentation are publicly available for certain of the compounds included on this slide. Please note that these results are taken from placebo-controlled trials, and these medications have not been tested in head-to-head assessments.

[1] Comi et al. Ann Neurol. 2001;49(3):290-297 [2] O'Connor et al. Neurology. 2006;66(6):894-900 [3] Kappos et al. Lancet. 2008;372(9648):1463-1472 [4] Kappos et al. N Engl J Med. 2006;355(11):1124-1140 [5] Cohen JA, Arnold DL, Comi G, et al. Lancet Neurol. 2016;15(4):373-381; QD: quaque die = once-daily; TID: ter in die = three times daily; RRMS: relapsing-remitting multiple sclerosis

ENSURE: Ongoing Pivotal Phase 3 Trials in Relapsing MS

NCT05134441 & NCT05201638



Coordinating Investigator

Robert J. Fox, M.D.
Cleveland Clinic



Included Patient Population: Relapsing Forms of MS

- Adult patients aged 18 to 55 years
- Established diagnosis of MS (revised McDonald criteria 2017)
- Confirmed relapsing MS (1996 Lublin criteria^[1])
- Active disease as defined by Lublin 2014
- EDSS score at screening between 0 to 5.5


[1] Lublin FD, et al. Neurology. 2014;83(3):278-286

MS: multiple sclerosis; EDSS: Expanded Disability Status Scale; QD: quaque die = once-daily



Two Multicenter, Randomized, Double-Blind Phase 3 Trials

- Approximately 1,050 patients in each trial
- More than 100 sites in the United States, Latin America, Central and Eastern Europe, and India in each trial
- Randomization to 30 mg vidofludimus calcium or placebo QD
- Completion ENSURE-1 expected in Q2/2026, ENSURE-2 in H2/2026



ENSURE: Positive Outcome of Interim Futility Analysis



- Unblinded Independent Data Monitoring Committee (IDMC) confirmed predetermined **futility criteria have not been met**
- IDMC recommended **continuing trial without changes**, including **no need for a potential upsizing**
- Based on a pre-specified assessment after approximately half of the planned first relapse events occurred in the double-blind treatment periods
- Based on a conditional power analysis by an unblinded IDMC
- Immunic has remained blinded and has not seen any of the data available to the IDMC to make their recommendations



Vidofludimus Calcium in Multiple Sclerosis (MS)

Development in Progressive Multiple Sclerosis (PMS)

Vidofludimus Calcium Could be the First Treatment Option for Non-Relapsing Secondary Progressive Multiple Sclerosis




Leveraging Nurr1 in a Population Without Focal Inflammatory Disease

- Currently, there is no treatment for non-relapsing SPMS and only one treatment for PPMS approved
- Therapies targeting relapses have not shown a clinical benefit in PMS
- Therefore, high unmet medical need and expected value for new PMS treatments
- Vidofludimus calcium has shown hints of neuroprotection in the phase 2 EMPHASIS trial in RRMS and in preclinical experiments
- CALLIPER designed to demonstrate vidofludimus calcium's neuroprotective potential and to open a quick path towards potential regulatory approval in PMS




Huge potential in PMS
First-in-disease potential in non-relapsing SPMS



Nurr1: nuclear receptor related 1; PMS: progressive multiple sclerosis; SPMS: secondary PMS; PPMS: primary PMS, RRMS: relapsing-remitting multiple sclerosis

CALLIPER: Ongoing Phase 2 Trial in Progressive MS

NCT05054140



Coordinating Investigator: Robert J. Fox, M.D., Cleveland Clinic

+EoMT: at W120 or when last enrolled patient reaches W72

BL: baseline; D: day; EoMT: end of main treatment period; EoS: end of study; MRI: magnetic resonance imaging; Gd+: gadolinium-enhancing; OLE: open-label extension; R: randomization; W: week; PPMS: primary progressive multiple sclerosis; SPMS: secondary progressive multiple sclerosis; EDSS: Expanded Disability Status Scale; QD: quaque die = once-daily



Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial

- 467 patients enrolled at more than 70 sites in North America, Western, Central and Eastern Europe
- Randomization to 45 mg vidofludimus calcium or placebo QD
- Primary endpoint: annualized rate of percent brain volume change up to 120 weeks
- Key secondary endpoint: time to 24-week confirmed composite disability progression
- Blinded main treatment period up to 120 weeks
- Optional, approximately 8-year, open-label extension period



Included Patient Population: Progressive Forms of MS


- Adult patients aged 18 to 65 years
- PPMS or SPMS diagnosis (revised McDonald criteria 2017)
- EDSS score at screening between 3.0 to 6.5
- No evidence of relapse in last 24 months before randomization
- Evidence of disability progression

CALLIPER: Patient Demographics and Baseline Characteristics

Total Study Population of 467 Enrolled Patients



Progressive Disease Subtypes



Baseline Characteristics


| Baseline Patient Characteristics | Total (N=467) |
|---|--------------------|
| Age [years], median (min-max) | 51.0 (21-65) |
| Gender (n and % female) | 302 (64.7%) |
| Race (n and % White) | 460 (98.7%) |
| BMI [kg/m^2], median (min-max) | 25.0 [15.8 – 46.6] |
| SDMT [points], median (min-max) | 35.0 [0-180] |
| EDSS at Visit 1, median (min-max) | 5.5 [2.5-6.5] |
| MS relapses during last 24 months, median (min-max) | 0.0 [0-1] |

Disease subtype information are used as diagnosis entered by investigator at study entry. Definition non-active SPMS (according to CALLIPER protocol): no evidence of relapse in the last 24 months before randomization, AND patients showing no evidence ofGd+MRI lesions in the brain or spinal cord in the last12 months; definition non-relapsing SPMS: no evidence of relapse in the last 24 months before randomization / BMI: body mass index; SDMT: Symbol Digit Modalities Test; EDSS: Expanded Disability Status Scale

PPMS Patients Treated with Ocrelizumab That Achieved Lower Levels of NfL Had a Lower Risk for Future Disability



Ocrelizumab ORATORIO Study in PPMS as Historical Comparison




- Blood NfL levels re-baselined at Week 48, an optimized cut-off was created between high (H) and low (L) NfL levels
- Patients then followed in continuing double-blind and/or OLE treatment with ocrelizumab, monitored for 24-week CDP over 8 years

Findings:

- Relationship found between Week 48 blood NfL and risk for subsequent 24-week CDP in PPMS patients
- **Patients with low NfL levels have a lower risk of future disability worsening**

Improvements in Serum NfL for Vidofludimus Calcium Consistent Throughout the Overall PMS Population and All Subtypes


Mean Change to Week 24 as Compared to Placebo in % of Baseline



Standard deviation for change from baseline in % of baseline: CALLIPER week 24: IMU-838 35.7%, PPMS: IMU-838 7.1%, n-aSPMS: IMU-838 14.7%, aSPMS: IMU-838 10.3%, 95% Hodges-Lehmann confidence bound EMPHASIS week 24 for 45mg IMU-838: lower boundary -41.0%, upper boundary -12.0%, includes all randomized patients with available neurofilament data at interim analysis, arithmetic mean value for group averages; aSPMS and n-aSPMS designation as per diagnosis by clinical investigator at study entry
NfL: neurofilament light chain; PMS: progressive multiple sclerosis; PPMS: primary PMS; SPMS: secondary PMS; n-a: non-active; a: active

NfL Reduction Compares Favorably with Other MS Therapies

CALLIPER Interim Data Compared to Select Historical Trials



CALLIPER: N = Number of patients in the 45 mg IMU-838 groups, only patients with both baseline and week 24 values considered for change from baseline analysis, arithmetic mean value for group averages; includes all randomized patients with available NfL data at interim analysis

Standard deviation for change from baseline in % of baseline: CALLIPER week 24: IMU-838 35.7%; 95% Hodges-Lehmann confidence bound EMPHASIS week 24 for 45mg IMU-838: lower boundary -41.0%, upper boundary -12.0%

ORATORIO: Bar-Or A. et al., EBioMedicine. 2023 Jul;93:104662; EXPAND: Leppert D., et al., Neurology. 2022 May 24;98(21):e2120-e2131; OBOE: Cross A. et al., Neurology Apr 2019, 92 (15 Supplement) S56.008; evobrutinib: Kuhle J. et al., AAN 2021 Virtual Congress

*plasma NfL levels; **12-month data, geometric mean; *** Displayed are data for subpopulation without relapses (n-aSPMS) and with relapses (aSPMS); NfL: neurofilament light chain; PPMS: primary progressive multiple sclerosis; SPMS: secondary progressive multiple sclerosis; n-a: non-active; a: active

Positive Interim Biomarker Data of Vidofludimus Calcium in Progressive Multiple Sclerosis



Biomarker evidence that vidofludimus calcium's activity extends beyond the previously observed anti-inflammatory effects, thereby further reinforcing its neuroprotective potential



Vidofludimus calcium aiming to address high unmet medical need in non-relapsing SPMS where no relevant treatments are available in the US



Overall CALLIPER trial ongoing; brain volume data of the full 467 patients expected in April 2025



Results of this interim analysis may inform the ability to potentially reduce PIRA events in the ongoing phase 3 ENSURE program in RMS




Vidofludimus Calcium: DHODH Inhibition Provides Broad-Spectrum Antiviral Activity Against Different Pathogenic Viruses



Inhibits Epstein-Barr Virus (EBV)
Replication and Reactivation


By targeting the host cell metabolism, vidofludimus calcium has shown to be active against different RNA and DNA viruses *in vitro*

- Shows antiviral activity with EC₅₀ values in single digit μM range
- Including strong anti-EBV activity



Showed Dose-Dependent
Inhibition of EBV Reactivation


Anti-Akata-BX1-EBV-GFP stimulated with hIgG



Decreased Number of Opportu-
nistic SARS-CoV-2 Infections


Vidofludimus calcium showed interesting hints for clinical anti-SARS-CoV-2 activity in the phase 2 EMPHASIS trial in RRMS

- Number of reported COVID-19 cases Cohort 2:



Left: Eur J Clin Invest. 2020;50:e13366 / middle: Marshall et al., Poster ECTRIMS 2021 / right: Immunic data; DHODH: dihydroorotate dehydrogenase; RNA: ribonucleic acid; DNA: deoxyribonucleic acid; EC50: half-maximal effective concentration; EBV: Epstein-Barr virus; hIgG: human immunoglobulin G; SARS-CoV-2: severe acute respiratory syndrome coronavirus; COVID-19: coronavirus disease 2019; RRMS: relapsing-remitting multiple sclerosis

Several Layers of Patents Protecting Vidofludimus Calcium



Eight Independent Patent Families Protecting Vidofludimus Calcium

- IP for superior calcium salt and specific polymorph of the drug product
 - Additional patent directed to specific polymorph matching the only polymorph in the drug product granted in the US and other jurisdictions
- Broad IP for all salts directed to dosing regimens, covers all label-relevant dosing schemes, granted in the US and Japan
- Dose strengths subject of another granted patent in the US
- Use of vidofludimus for treating PIRA as well as other neurodegenerative diseases, also including biomarker-based subgroups, filed in 2023
- Another level of protection expected by data exclusivity based on vidofludimus calcium's classification as New Chemical Entity (NCE)



Patent portfolio expected to provide exclusivity into 2041 in the US, unless extended further

IP: intellectual property; MS: multiple sclerosis; RMS: relapsing MS; PMS: progressive MS; SPMS: secondary progressive MS; PPMS: primary progressive MS; PIRA: progression independent of relapse activity

Phase 3 Pipeline of Oral DMTs in Both RMS and PMS: Vidofludimus Calcium Is the Only Non-BTKi

Nurr1 Activator / DHODH Inhibitor

Vidofludimus Calcium
Phase 3 & Phase 2



RELAPSING MS (ENSURE-1 & ENSURE-2)

Completion expected 2026

PROGRESSIVE MS (CALLIPER)

Data expected April 2025

BTK Inhibitor

Telebrutinib | Phase 3

sanofi

Acquired from
Principia for \$3.7 billion

RELAPSING MS (GEMINI 1 & GEMINI 2)

Data reported September 2024

nrSPMS (HERCULES)

Data reported September 2024

PPMS (PERSEUS)

Data expected July 2025

Fenebrutinib | Phase 3



RELAPSING MS (FENhance 1 & FENhance 2)

Data expected Q4/2025


PPMS (FENtrepid)

Data expected Q4/2025

DMT: disease-modifying therapy; RMS: relapsing MS; PMS: progressive MS; nrSPMS: non-relapsing secondary progressive MS; PPMS: primary progressive MS; BTKi: Bruton Tyrosine Kinase inhibitor; Nurr1: nuclear receptor related 1; DHODH: dihydroorotate dehydrogenase

Vidofludimus Calcium in Multiple Sclerosis

Consistent and Differentiated Results to Date Support Straightforward Path Towards Potential Regulatory Approvals



Although we currently believe that each of these goals is achievable, they are each dependent on numerous factors, most of which are not under our direct control and can be difficult to predict. We plan to periodically review this assessment and provide updates of material changes as appropriate. / MS: multiple sclerosis; RRMS: relapsing-remitting MS; RMS: relapsing MS; PMS: progressive MS; NfL: neurofilament light chain



IMU-856

Restoring a Healthy Gut through Renewal of the Bowel Wall

IMU-856 Could Be the Perfect New Solution for Treating Gastrointestinal Disorders Without Harming the Immune System



- Innovative oral therapeutic approach applicable to a broad range of gastrointestinal disorders




- Targets physiological intestinal epithelial regeneration



- Achieves gut wall healing without immunosuppression


Once-Daily, Oral IMU-856 Aims to Regenerate the Gut Wall and Barrier Function by a New Innovative Targeted Mechanism

Damaged Gut Wall



IMU-856

Healthy Gut Wall



IMU-856:

- First-in-class modulator of sirtuin 6 (SIRT6), targets physiological intestinal epithelial regeneration and restoration of barrier function
- Provides protection and enhances transport of nutrients
- This new approach avoids immunosuppression

IMU-856 Uniquely Suited for Potential Use in a Broad Spectrum of Serious Gastrointestinal Diseases

Demonstrated clinical proof-of-concept: Positive effects shown in a phase 1b clinical trial on **gastrointestinal architecture and function** applicable to multiple diseases with histological damage

Celiac Disease

>2 million patients^[1]

- High unmet medical need, currently no approved drugs
- Phase 2 trial to demonstrate histological and functional improvement in patients with ongoing active celiac disease

Inflammatory Bowel Disease

>1 million patients^[2]

- Potential synergies in combination with IL-23 or anti-integrin treatments to break efficacy ceiling

Graft-Versus-Host-Disease



High-value orphan indication

- High unmet medical need indication with large commercial potential
- Potential for rapid assessment in a small study

[1] <https://www.niddk.nih.gov/health-information/digestive-diseases/celiac-disease/definition-facts> [2] Lewis JD, et al. Gastroenterology. 2023;165(5):1197-1205.e2

SIRT6 Target Is Selectively Expressed in Gut Epithelial Cells

Highest mRNA Expressions in Paneth Cells, Enterocytes and Goblet Cells



Left: <https://www.proteinatlas.org/> / Right: Peterson, L., Artis, D. Nat Rev Immunol 14, 141–153 (2014); mRNA: messenger ribonucleic acid


IMU-856 Enhances the Natural Regenerative Process in the Gut

Gut wall renewal is a normal physiological process

1. Regeneration begins in the crypts, where intestinal stem cells are located
2. Stem cells undergo asymmetric division thereby producing fully differentiated epithelial gut cells and renewing intestinal stem cells
3. These new epithelial cells are renewing the lining of crypts and villi to maintain healthy gut and proper intestinal barrier

→ IMU-856 is an epigenetic regulator which enhances this natural tissue renewal phenotype

Asymmetric cell division renews stem cells and regenerates the gut wall




Adapted from Mamis K et al., Proc. R. Soc. B. 290:20231020 (2023)

Celiac Disease Currently Has No Adequate Treatment Options

- Two million patients diagnosed with celiac disease in the US; more than one million more undiagnosed^[1,2]
- Most studies report between **24% and 47%**^[3-8] of patients with signs and symptoms of ongoing active celiac disease (OACD) **despite a gluten-free diet**, most likely due to continuous (inadvertent) gluten exposure
- **Only established therapeutic option is a life-long strict adherence to a gluten-free diet**^[9], which involves complete avoidance of proteins from wheat, barley, and rye
- Gluten challenge is an accepted concept for clinical trials in celiac disease

10 mg of gluten is the total limit for all foods combined for the entire day.




How much is 10 mg of gluten?

[1] Singh et al., Clinical Gastroenterology and Hepatology 2018;16:823–836 [2] Choung et al., Mayo Clin Proc. 2016 Dec 5:S0025-6196(16)30634-6 [3] Lebowitz et al., Aliment Pharmacol Ther. 2014 March ; 39(5): 488–495 [4] Lanzini et al., Aliment Pharmacol Ther. 2009; 29(12):1299–308 [5] Ciacci et al., Digestion. 2002; 66(3):178–85 [6] Selby et al., Scand J Gastroenterol. 1999; 34(9):909–14 [7] Rubio-Tapia et al., Am J Gastroenterol. 2010; 105(6):1412–20 [8] Sharkey et al., Aliment Pharmacol Ther. 2013; 38(10):1278–91 [9] <https://nationalceliac.org/celiac-disease-questions/understanding-gluten-levels/> (text and picture)

First Proof-of-Concept for Gastrointestinal Disorders in Celiac Disease

Celiac Disease is a Serious Life-Long Disease



Celiac disease is a **multifactorial, complex autoimmune disease** caused by an immune reaction against a degradation product of gluten and is strongly associated with **specific HLA class II gene variants** (HLA-DQ2 and -DQ8)^[1]

- 1** ■ Gluten is degraded into **gliadin peptides** which are taken up by the bowel epithelium (trans- or paracellular)
- 2** ■ In patients with a specific HLA protein (DQ2 and DQ8) composition, deaminated gliadin (by TG2) is recognized by CD4+ T cells and can trigger an immune response which leads upon continued gliadin uptake to
 - **Increased intestinal permeability**
 - **Epithelial and mucosal damage** with negative changes of the gut architecture, including villous atrophy leading to malabsorption of nutrients
- 3** ■ Hypothesis for IMU-856's mode of action:
 - Restores villous architecture by triggering regenerative processes of the epithelial lining
 - Improves intestinal barrier function

Picture: self-drawn; [1] Caio et al. BMC Medicine (2019) 17:142

HLA: human leukocyte antigen; TG2: tissue transglutaminase 2; CD: cluster of differentiation; IL: interleukin


IMU-856 Demonstrated Clinical Proof-of-Concept in a Phase 1b Clinical Trial in Celiac Disease



Proof-of-Concept Study Designed as a Gluten Challenge Trial


- **Celiac disease used as disease model to provide clinical proof-of-activity of IMU-856 in a 28-day trial setting**
- Designed to explore effects of gluten challenge in a celiac disease patient population
- Dosing: 80 and 160 mg QD of IMU-856, or placebo
- 43 patients enrolled (IMU-856: N=29)
- Assessed safety, tolerability, pharmacokinetics, and pharmacodynamics of IMU-856
- Proof-of-concept: measured histological changes, blood biomarkers of epithelial mass, nutrient uptake and disease-related symptoms

Flow Chart of Phase 1b Clinical Trial in Celiac Disease




QD: quaque die = once-daily; EGD: esophagogastroduodenoscopy

IMU-856 Showed Positive Effects in Four Main Dimensions of Clinical Outcome in Celiac Disease Patients



IMU-856 Protected Against Gluten-Induced Decrease in Villous Height as Compared to Placebo

Absolute change in villous height (μm) between Baseline and Day 29



Day 1-28: Treatment IMU-856/placebo

Day 14-28:
Gluten challenge with 6 g/daily

Baseline:
EGD with biopsy

Visit 6 / Day 29:
EGD with biopsy


- Substantial protection for IMU-856 treatment groups as compared to placebo
- Reached statistical significance* for this objective readout which is known to be relevant to influence future medical complications of celiac disease
- Assessed by central pathology laboratory and blinded pathology reader

* Wilcoxon Two-Sample Test comparison between pooled IMU-856 groups and placebo, performed as post-hoc exploratory statistical analysis

Disease Analysis Set: N=35/43 included in histology analysis set. 8 patients not included in this analysis due to early termination. Gluten Challenge for 15 days with 6g daily. Central pathology laboratory: Jilab Inc. Tampere, Finland
EGD: esophagogastroduodenoscopy; SD: standard deviation

IMU-856 Improved Citrulline Levels Despite Gluten Challenge

Biomarker Reflecting the Health Status and Function of Enterocytes



Plasma citrulline levels are known to be related to intestinal epithelial mass and function^[1]


- Citrulline levels increase with improvement of enteropathy^[2]
- IMU-856 increased citrulline levels dose proportionally (despite gluten challenge), whereas being reduced in placebo patients

[1] Singh et al., J. Clin. Med. 2019, 8, 885; doi:10.3390/jcm8060885 [2] Fragkos et al., United Eur. Gastroenterol. J. 2018, 6, 181–191 &/ Number of Patients: Placebo: N=13 for Mean Change Baseline to Day 14, N=11 for Mean Change Baseline to Day 29; IMU-856 80 mg: N=14 for Mean Change Baseline to Day 14, N=11 for Mean Change Baseline to Day 29; IMU-856 160 mg: N=13 for Mean Change Baseline to Day 14, N=13 for Mean Change Baseline to Day 29; SD: standard deviation


IMU-856 Improved Uptake of Actively Transported Essential Nutrients Vitamin B12 and Zinc



Vitamin B12



Zinc



SD: standard deviation

IMU-856 Could Become a Game Changer for the Treatment of Gastrointestinal Disorders



- IMU-856 is poised to be a **potential paradigm shift** in how to treat gastrointestinal diseases.
- Dozens of endpoints were investigated in this proof-of-concept trial and all demonstrated that **IMU-856 has a beneficial effect** in the treated celiac disease patients.
- IMU-856 was shown to be **safe and well-tolerated** in this trial.
- Immunic is **preparing clinical phase 2 testing** of IMU-856.
- IMU-856 has the potential for broad development where renewal of the gut wall is important; **multiple indications** are under evaluation.



Immunic Therapeutics

Summary

Summary: Vidofludimus Calcium Is a Derisked Near-Term Opportunity



Innovative clinical pipeline: First-in-class oral drugs with unique modes of actions for multiple sclerosis and gastrointestinal diseases in various phases of clinical development



Relapsing MS opportunity is meaningful and de-risked:

Oral category going to remain a large portion of overall MS market; peak sales potential for vidofludimus calcium of \$2-6 billion

Currently available oral therapies have limitations in benefit/risk profile; there is need for improvement

Vidofludimus calcium has the potential to address these shortcomings and transform the oral MS DMT market

ENSURE program: Two identical phase 3 clinical trials, designed to achieve potential regulatory approval of vidofludimus calcium in relapsing MS in a low-risk study design; completion of both ENSURE trials expected in 2026



Progressive MS provides tremendous upside opportunity:

High unmet medical need market: No approved therapies for non-relapsing SPMS; one approved therapy for PPMS (infusion)

Peak sales potential for vidofludimus calcium of \$2-4 billion across respective indications

CALLIPER trial designed to demonstrate vidofludimus calcium's potential for neuroprotective activity in a non-relapse setting

Top-line data from CALLIPER trial expected in April 2025



Cash runway into Q3/2025

Cash position: USD 79.7 million (as of June 30, 2024), shares outstanding: 90,079,016 (as of July 31, 2024)

Thank You!



Jessica Breu

Vice President Investor
Relations & Communications

Phone: +1-332-255-9819

Email: ir@imux.com

Web: www.imux.com

Immunic, Inc.

1200 Avenue of the Americas
New York City, NY 10036
USA

Immunic AG

Lochhamer Schlag 21
82166 Gräfelfing (Munich)
Germany

Immunic Australia Pty. Ltd.
Melbourne
Australia

